

Pharmacy and Therapeutics Committee

Meeting Minutes

Thursday, November 15, 2018
7:00 a.m. to 8:45 a.m.
Cannon Health Building
Room 125

Committee Members Present:

McKay Robinson, PharmD
Clayton Grace, RPh
Cole Sloan, PharmD
Susan Siegfried, MD

Bryan Larson, PharmD
Clinton Sheffield, MD
Elizabeth Young, PharmD

Committee Members Excused:

Jake Jones, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Joe Busby, RPh, MBA

Andrea Rico, CPhT

University of Utah Drug Regimen Review Center Staff Presenter:

Valerie Gonzales, PharmD

Other Individuals Present:

Jason Bott, Lilly
Chris Stanfield, Supernus
Karen Campbell, Allergan
Diann Matthews, Merz
Anthony Wheeler, Lilly
Rob Booth, Allergan
Maria Agapova, Teva
Lauren Heath, U of U COP

Chi Kohlhoff, Braeburn
Michael Faithe, Amgen
Chris Anstead, Amgen
Jennifer Lauper, BMS
Josh Whittington, BMS
Charissa Anné, J&J
Cody Ball, Select Health

Meeting conducted by: McKay Robinson

1. **Welcome & Housekeeping:** McKay Robinson opened the meeting and announced a quorum.
2. **Review and Approval of October Minutes:** Clinton Sheffield made a motion to approve the minutes from October. Susan Siegfried seconded the motion. Five in favor with Susan Siegfried and Clayton Grace abstaining, motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Macrolide antibiotics. Next month, the DUR board will discuss migraine prophylactic treatments.
4. **FDA-Approved Agents for Migraine Prophylaxis:** (divalproex, erenumab-

aooe, galcanezumab-gnlm, fremanezumab-vfrm, onabotulinumtoxin A, propranolol, timolol, topiramate). Valerie Gonzales presented a review of FDA-approved agents for migraine prophylaxis. She presented peer reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. Public Comment:

- a. Maria Agapova, MSc, PhD from Teva presented information pertaining to Ajovy.
- b. Karen L. Campbell, PharmD from Allergan presented information pertaining to Botox.
- c. Anthony Wheeler, PhD from Lilly presented information pertaining to Emgality.
- d. Michael, Faithe from Amgen presented information pertaining to Aimovig.

6. Other State Report: Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.

7. Committee Discussion:

- a. Bryan Larson suggested that it may be helpful to providers if agents that fit in multiple classes are listed in both classes where they fit. For example, divalproex listed with anticonvulsants as well as migraine prophylaxis treatments. Clinton Sheffield and others generally agreed with this suggestion. No motion was made.
- b. Bryan Larson questioned whether it would be better to include only FDA approved agents in a PDL class, or to also include agents with strong evidence supporting their use for migraine prophylaxis. Clinton Sheffield and others were supportive of also including agents such as amitriptyline in the same class.
- c. Bryan Larson asked whether the oral and injectable agents should be considered jointly or separately with regard to safety and efficacy, or for listing on the PDL. Elizabeth Young suggested that they be considered separately. Bryan Larson discussed the functional differences of listing oral and injectables in the same class vs. different classes. Clinton Sheffield indicated that listing all agents in a single class is fine. General consensus was that safety and efficacy of oral and injectable agents would be better to consider separately.
- d. Elizabeth Young asked whether onabotulinumtoxin is covered under the medical or pharmacy benefit. Bryan Larson stated that he believes it is on the pharmacy benefit. Merelyn Berrett and Heather Santacruz confirmed this.
- e. Committee members discussed the general lack of data regarding this issue. It was generally agreed that it would be advisable to revisit this topic when more data is available. No motion was made.
- f. Elizabeth Young made a motion that all oral agents are equally safe and efficacious for the treatment of migraine. Clinton Sheffield seconded. Unanimous approval, motion passed.
- g. Clinton Sheffield made a motion that all injectable agents are equally safe and efficacious, but we still have limited evidence regarding their place in therapy and recommend that the DUR Board review these therapies. Bryan Larson seconded. Unanimous approval, motion passed.

8. **Public Meeting Adjourned:** McKay Robinson motioned to adjourn the meeting. Bryan Larson seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for** March 21, 2019 Insulins - Rapid Acting, Insulins - Basal, ACE Inhibitors/ACE Inhibitor Combinations.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>

PENDING